The Latest Breaking News from FDA

Here's a roundup of top developments in the biotech space over the last 24 hours:

Turning Point Therapeutics, Inc. (NASDAQ: TPTX) received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for its lead drug candidate Repotrectinib in Patients With One Prior ROS1 Tyrosine Kinase Inhibitor and no Prior Chemotherapy.

US customers started deluging Mexican border pharmacies after Texas passed an anti-abortion law last fall. A two-pill combination costs about $400 and does not require a doctor's prescription.

Strained supplies are further exacerbated after a recall by manufacturer Abbott, experts say

DENVER — The nicotine landscape in Colorado is likely to change in the near future, but how much depends on what lawmakers do in the final days of this year’s legislative session.

LogicBio Therapeutics Inc (NASDAQ: LOGC) shares are trading higher by 63.48% at $0.81 after the company announced the FDA lifted the clinical hold on its LB-001 Investigational New Drug Application, allowing patient enrollment to resume in the Phase 1/2 SUNRISE trial for pediatric patients with methylmaloni

In today's Inverse Daily, read science stories on NASA’s Moon woes, hidden delights under the Antarctica ice sheet, and female reproductive healthcare.

The FDA has lifted the clinical hold on LogicBio Therapeutics Inc's (NASDAQ:LOGC) LB-001 Investigational New Drug Application (IND) to resume patient enrollment in Phase 1/2 SUNRISE trial in pediatric methylmalonic acidemia patients.  Methylmalonic acidemia is an inherited disorder in which the body cannot process certain proteins and fats (lipids) properly. The FDA acknowledged that…

  The U.S. Food and Drug Administration (FDA) has lifted the clinical hold on LogicBio Therapeutics’ (NASDAQ: LOGC) Investigational New Drug Application (IND) of its drug candidate LB-001 for pediatric patients with methylmalonic acidemia.